Table 2.

Bivariate analysis of variables according to school and work attendance status (n=107)

Variable	Absents (n=47), n (%)	Attended (n=60), n (%)	P*
Demography
Gender
Male	26 (55)	34 (56.7)	0.89
Female	21 (45)	26 (55.3)
Nationality
Saudi	37 (78.7)	47 (78.3)	0.96
Non-Saudi	10 (21.3)	13 (21.7)
Age category (years)
0-18	9 (19)	15 (25)	0.41
18-40	31 (66)	32 (53.3)
40-60	7 (15)	13 (21.7)
Smoking
Yes	10 (21.3)	12 (20)	0.87
No	37 (78.7)	48 (80)
Family history of IBD
Yes	2 (4.3)	8 (13.3)	0.11
No	45 (95.7)	52 (86.7)
Clinical features
Diagnosis
Crohn’s disease	35 (74.5)	28 (46.7)	0.004**
Ulcerative colitis	12 (25.5)	32 (53.3)
CD location
L1: Terminal Ileal	1 (2.8)	2 (7.1)	0.08
L2: Colonic	17 (48.6)	20 (71.4)
L3: Ileo-colonic	17 (48.6)	6 (21.4)
Perianal disease
Yes	9 (19.1)	3 (5.0)	0.02**
No	38 (80.9)	57 (95)
CD disease behavior
B1. Nonstricturing nonpenetrating	24 (68.6)	18 (64.3)	0.66
B2. Stricturing	4 (11.4)	2 (7.1)
B3. Penetrating	7 (20)	8 (28.6)
Disease Extension (UC)
E1. Ulcerative proctitis	0 (0.0)	1 (3.1)	0.23
E2. Left-sided UC	9 (75)	15 (46.9)
E3. Pancolitis	3 (25)	16 (50)
IBD disease severity
Mild to moderate	25 (53.2)	38 (63.3)	0.29
Severe	22 (46.8)	22 (36.7)
Extraintestinal manifestations
Yes	15 (31.9)	8 (13.3)	0.02**
No	32 (68.1)	52 (86.7)
Medical treatment
Mesalamine
Yes	17 (36.2)	19 (31.7)	0.63
No	30 (63.8)	41 (68.3)
Azathioprine
Yes	17 (36.2)	23 (38.3)	0.82
No	30 (63.8)	37 (61.7)
Adalimumab
Yes	12 (25.5)	15 (25)	0.95
No	35 (74.5)	45 (75)
Infliximab
Yes	11 (23.4)	7 (11.7)	0.11
No	36 (76.6)	53 (88.3)
Surgery
Colectomy
Yes	4 (8.5)	3 (5.0)	0.47
No	43 (91.5)	57 (95)
Small bowel resection
Yes	1 (2.1)	2 (3.3)	0.71
No	46 (97.9)	58 (96.7)

*Chi-square/Fisher’s exact tests; **P<0.05. CD – Crohn’s disease; IBD – Inflammatory bowel disease; UC – Ulcerative colitis